Education
About Us
Working with TipRanks
Follow Us
Rhythm Pharmaceuticals Inc (RYTM)
NASDAQ:RYTM
RYTM Stock Chart & Stats
$107.42
-$0.41(-0.68%)
At close: 4:00 PM EST
$107.42
-$0.41(-0.68%)
Day’s Range― - ―
52-Week Range$45.91 - $116.00
Previous CloseN/A
Volume91.33K
Average Volume (3M)682.09K
Market Cap
$7.26B
Enterprise Value$6.54B
Total Cash (Recent Filing)$416.05M
Total Debt (Recent Filing)$151.00M
Price to Earnings (P/E)―
Beta1.72
Next Earnings
Mar 04, 2026EPS Estimate
-0.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.82
Shares Outstanding66,736,050
10 Day Avg. Volume693,545
30 Day Avg. Volume682,093
Financial Highlights & Ratios
PEG Ratio-0.37
Price to Book (P/B)20.75
Price to Sales (P/S)26.24
P/FCF Ratio-29.98
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue37.49
Enterprise Value/Gross Profit41.93
Enterprise Value/Ebitda-38.67
Forecast
1Y Price Target
$125.42Price Target Upside16.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-3.11
Revenue Forecast (FY)$187.83M
Bulls Say, Bears Say
Bulls Say
Long-term GrowthNext generation compounds bivamelagon and RM-718 offer long-term growth potential with patent protection extending into the 2040s.
Market ExpansionThe unmet need in hypothalamic obesity is high and would meaningfully expand the market opportunity.
Regulatory ApprovalImcivree is currently under regulatory review for acquired hypothalamic obesity with a high probability of approval and a strong commercial launch expected.
Bears Say
Financial PerformanceThe company reported a 3Q25 net loss of $0.82 per share, moderately wider than the forecast for a net loss of $0.72 per share.
International RevenueInternational revenues decreased by 21% due to variability in ordering patterns and a one-time pricing adjustment in France.
Regulatory DelayFDA delayed the setmelanotide (SET) PDUFA for acquired hypothalamic obesity (HO) to 3/20/26 from 12/20/25.
Rhythm Pharmaceuticals News
RYTM FAQ
What was Rhythm Pharmaceuticals Inc’s price range in the past 12 months?
Rhythm Pharmaceuticals Inc lowest stock price was $45.91 and its highest was $116.00 in the past 12 months.
What is Rhythm Pharmaceuticals Inc’s market cap?
Rhythm Pharmaceuticals Inc’s market cap is $7.26B.
When is Rhythm Pharmaceuticals Inc’s upcoming earnings report date?
Rhythm Pharmaceuticals Inc’s upcoming earnings report date is Mar 04, 2026 which is in 96 days.
How were Rhythm Pharmaceuticals Inc’s earnings last quarter?
Rhythm Pharmaceuticals Inc released its earnings results on Nov 04, 2025. The company reported -$0.82 earnings per share for the quarter, missing the consensus estimate of -$0.708 by -$0.112.
Is Rhythm Pharmaceuticals Inc overvalued?
According to Wall Street analysts Rhythm Pharmaceuticals Inc’s price is currently Undervalued.
Does Rhythm Pharmaceuticals Inc pay dividends?
Rhythm Pharmaceuticals Inc does not currently pay dividends.
What is Rhythm Pharmaceuticals Inc’s EPS estimate?
Rhythm Pharmaceuticals Inc’s EPS estimate is -0.79.
How many shares outstanding does Rhythm Pharmaceuticals Inc have?
Rhythm Pharmaceuticals Inc has 66,736,050 shares outstanding.
What happened to Rhythm Pharmaceuticals Inc’s price movement after its last earnings report?
Rhythm Pharmaceuticals Inc reported an EPS of -$0.82 in its last earnings report, missing expectations of -$0.708. Following the earnings report the stock price went down -7.693%.
Which hedge fund is a major shareholder of Rhythm Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in RYTM
Rhythm Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$125.42 (16.76% Upside)
$125.42 (16.76% Upside)
Blogger Sentiment
Bullish
RYTM Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 123.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
77.81%
12-Months-Change
Fundamentals
Return on Equity
-240.36%
Trailing 12-Months
Asset Growth
39.41%
Trailing 12-Months
Company Description
Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of rare genetic disorders of obesity. The company operates primarily in the biotechnology sector and is committed to addressing unmet medical needs in patients suffering from these conditions. Rhythm's core product, Imcivree (setmelanotide), is specifically designed to target the underlying biological mechanisms of obesity due to certain genetic causes, enhancing patient outcomes and quality of life.
RYTM Company Deck
RYTM Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Rhythm Pharmaceuticals demonstrated strong revenue growth and regulatory progress, particularly for IMCIVREE in hypothalamic obesity. While international revenue faced challenges, the company's successful equity offering and promising data in BBS highlight a positive outlook. R&D costs are rising, but the overall sentiment remains optimistic.View all RYTM earnings summariesRYTM Stock 12 Month Forecast
Average Price Target
$125.42
▲(16.76% Upside)
Technical Analysis
Cytokinetics
―
TG Therapeutics
―
Legend Biotech
―
Avidity Biosciences
―
Abivax SA Sponsored ADR
―
Ownership Overview
Currently, No data available
---